Programme

Registration, Posters Set-Up & Opening Remarks

SESSION 1:
OPENING PLENARY SESSION

Moderator: To be confirmed

KEYNOTE:
‘Pushing the envelope of HIV-1 vaccine design’
Richard Wyatt
(Scripps Research Institute, La Jolla, California, USA)

KEYNOTE:
‘Conventional and unconventional VLP based strategies for development of HIV vaccines’
Bryce Chackerian¹, Alemu Mogus¹, Julianne Peabody¹, Larance Ronsard³, David Peabody¹, Moriya Tsuji² and Daniel Lingwood³
(¹ University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; ² Aaron Diamond AIDS Research Center, New York, USA; ³ The Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA)

KEYNOTE:
‘A next generation Alzheimers vaccine’
Martin Bachmann
(University of Bern, Bern, Switzerland)

Lunch Break & Posters

SESSION 2:
DESIGN/DEVELOPMENT/PRODUCTION

Moderator: To be confirmed

‘VLPs of ssRNA phages: Diversity, strucure and applications in vaccine development’
Kaspars Tars
(University of Latvia, Riga, Latvia)

‘Design of hepatitis B virus-like particles (VLPs) to optimise immunisation outcomes for preventative or therapeutic applications’
Hans Netter
(Peter Doherty Institute, Melbourne, Victoria, Australia)

‘A strategy for the design of genetically thermo-stabilised, immunogenic poliovirus empty capsids for use as VLP vaccines’
Helen Fox, Sarah Knowlson, Philip Minor and Andrew J. Macadam
(Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK)

Tea Break & Posters

SESSION 3:
VLP VACCINES

Moderator: To be confirmed

‘VLP-based vaccines for cardiovascular disease’
Alexandra Fowler¹, Erin Crossey¹, Maureen Sampson², Marcelo Amar², John Schiller³, Koen Van Rompay⁴, Alan Remaley² and Bryce Chackerian¹
(¹ University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; ² NIH/NHLBI, Bethesda, Maryland, USA; ³ NIH/NCI, Bethesda, Maryland, USA; ⁴ California Regional Primate Center, Davis, California, USA)

‘Liposome-adjuvanted Self-Assembling Protein Nanoparticles (SAPN) for HIV-1 Vaccine Development’
Zoltan Beck 
(US Military HIV Research Program (MHRP), Laboratory of Antigen and Adjuvant Research, Walter Reed Army Institute of Research (WRAIR), Silver Spring, Maryland, USA)

‘Exploiting Pichia pastoris for production of a VLP vaccine against poliomyelitis’
Lee Sherry¹, Keith Grehan¹, Helen Fox², Mohammad W. Bahar³, Elizabeth E. Fry³, David I. Stuart³, Andrew J. Macadam², David J. Rowlands¹
and Nicola J. Stonehouse¹
(¹ School of Molecular and Cellular Biology, University of Leeds, Leeds, UK; ² Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK; ³ Division of Structural Biology, University of Oxford, Oxford, UK)

SESSION 4:
PLANT-BASED VLPS

Moderator: To be confirmed

‘Plant VLPs in vaccine development’
Andris Zeltins
(University of Latvia, Riga, Latvia)

‘Plant based norovirus VLPs: From molecule design to phase I clinical trials’
Franziska Jarczowski
(Icon Genetics GmbH, Halle (Saale), Germany)

‘The suitability of plants for the production of Dengue Virus-like particles’
Daniel Ponnorf¹, Yulia Meshcheriakova¹, Hadrien Peyret¹ and George P. Lomonossoff¹
(¹ Department for Biological Chemistry, John Innes Centre, Norwich, UK; ² Plant Bioscience Ltd., Norwich Research Park, Norwich, UK)

‘The efficacy of a plant-produced virus-like particle vaccine against H6 avian influenza in specific-pathogen-free chickens’
T. Smith^1,2, M.M. O’Kennedy^1,2, D.B.R. Wandrag¹, M. Adeyemi¹ and C. Abolnik¹
(¹ Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, South Africa; ² NextGen Health, Council for Scientific and Industrial Research, Pretoria, South Africa)

Coffee Break & Posters

SESSION 5:

Moderator to be confirmed

‘Affinity-selection on the MS2 VLP platform as a means for producing molecular mimics of vaccine antigens’
David Peabody
(University of New Mexico, Albuquerque, New Mexico, USA)

‘Monoclonal antibody – equivalent performance of IL17 – targeting VLP-vaccines’
Alexandra Moleda, Andris Zeltins, Martin Bachman and John Foerster
(University of Dundee, Dundee, Scotland, UK)

‘Immunological characterization of GMMA-based vaccines’
O. Rossi, M.G. Aruta, F. Mancini, A. Acquaviva, F. Citiulo, A. Podda, L.B. Martin, F. Micoli and F. Necchi
(GSK Vaccines Institute for Global Health S.r.l. (GVGH), Siena, Italy)

Lunch Break & Posters

SESSION 6:

Moderator: To be confirmed

‘Adjuvanted virosome VLP as flexible and potent universal vaccine platform for induction of systemic and mucosal immunity’
Mario Amacker, Toon Stegmann, Ronald Kempers and Sylvain Fleury
(Mymetics SA, Epalinges, Switzerland and Mymetics B.V., Leiden, The Netherlands)

‘1918 influenza Virus-Like Particle Vaccine structural analysis by cryo-electron microscopy with implications for viral surface glycoprotein vaccines’
Audray K. Harris, Dustin M. McCraw, John R. Gallagher, Udana Torian, Mallory L. Myers, Michael T. Conlon and Neetu M. Gulati
(Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA)

‘Live vaccine based on probiotic Enterococcus L3 strain containing conservative epitopes of influenza virus neuraminidase’
Yulia Desheva
(Institute of Experimental Medicine, St. Petersburg, Russian Federation)

Tea Break & Posters

SESSION 7:
VLP VACCINES

Moderator: To be confirmed

‘Exploration and development of a novel personalized breast-cancer vaccine based on virus-like particles by incorporating tumor-specific T-cell epitopes’
Mona O. Mohsen¹, Monique Vogel¹, Said Dermime², Varghese Inchakalody², Daniel Speiser³, Alexander Knuth², Michal Bassani³ and Martin F. Bachmann¹
(¹ Department of BioMedical Research, Immunology RIA, University of Bern, Bern, Switzerland; ²Interim Translational Research Institute “iTRI”, National Center for Cancer Care & Research (NCCCR), Doha, State of Qatar; ³ Department of Oncology, University of Lausanne, Lausanne, Switzerland)

‘Bacteriophage virus-like particle vaccines for opioids’
Kathryn M. Frietze
(University of New Mexico School of Medicine, Albuquerque, New Mexico, USA)

‘Novel HBV S/preS1 chimeric antigen particles produced in mammalian cells and plants induce stronger immune response than the standard vaccine, S’
Mihaela-Olivia Dobrica¹, Catalin Lazar¹, Lisa Paruch², Andre van Eerde², Hege Steen², Sissel Haugslien², Catalin Tucureanu³, Iuliana Caras³, Sonya Ciulean³, Adrian Onu³, Crina Stavaru³, Alexandru Branzan⁴, Jihong Liu Clarke² and Norica Nichita¹
(¹ Institute of Biochemistry of the Romanian Academy, Bucharest, Romania; ² NIBIO – Norwegian Institute for Bioeconomy Research, Ås, Norway; ³ “Cantacuzino” National Research Institute, Bucharest, Romania; ⁴ Institute of Biology of the Romanian Academy, Bucharest, Romania)

SESSION 8:

Moderator to be confirmed

‘Self-emulsifying adjuvant systems (SE-AS) containing alpha-tocopherol show comparable immune responses to AS03’
Rushit N. Lodaya¹, Mansoor M. Amiji² and Derek T. O’Hagan¹
(¹ GSK, Slaoui Centre for Vaccines Research, Rockville, Maryland, USA; ² Northeastern University, Department of Pharmaceutical Sciences, Boston, Massachusetts USA)

‘Bioengineering rabbit hemorrhagic disease virus capsid to generate a multivalent immune response against foreign B-cell epitopes’
María Zamora-Ceballos, Noelia Moreno, Jose R.Castón, Alí Alejo, Esther Blanco and Juan Bárcena
(Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain)

‘VLP vaccine against influenza’
Anna Kirsteina
(University of Latvia, Riga, Latvia)

Coffee Break & Posters Breakdown

SESSION 9:
LATEBREAKER PRESENTATIONS

Moderator: To be confirmed

‘Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis’
Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)

Latebreaker abstracts for oral and poster presentation at VLPNPV 2022 are called for. Please see the Participation page for details.

‘Plug and Play platform technology for rapid response to emerging pathogens’
Mirriam Tacken¹, Benjamin Gutjahr³, Paul Wichgers Schreur¹, Lucien van Keulen¹, Jet Kant¹, Sandra van de Water¹, Yanyin Lin¹, Markus Keller³, Martin Groschup³, Martin Eiden³, Melanie Rissmann³, Felicitas von Arnim³, Rebecca König³, Alexander Brix⁴, Catherine Charreyre⁵, Jean-Christophe Audonnet⁵
and Jeroen Kortekaas^1,2
(¹ Department of Virology, Wageningen Bioveterinary Research, Lelystad, The Netherlands; ²Laboratory of Virology, Wageningen University and Research, Wageningen, The Netherlands; ³Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany; ⁴Boehringer Ingelheim, Hannover, Germany; ⁵ Boehringer Ingelheim, Lyon, France)